STDY STEADYMED LTD

STEADYMED LTD. INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law Violations

OAKLAND, Calif.--(BUSINESS WIRE)--

Girard Gibbs LLP is investigating claims on behalf of investors of SteadyMed Ltd. (NASDAQ: STDY) regarding possible violations of federal securities laws following the FDA’s refusal to review the company’s new drug application for Trevyent.

To speak privately with an attorney regarding this class action lawsuit investigation, click here.

On August 31, 2017, SteadyMed announced that it had received a Refusal to File letter from the FDA regarding the company’s New Drug Application for Trevyent, a treatment for pulmonary arterial hypertension. Specifically, the FDA determined, based on a preliminary review of the New Drug Application, that it was not complete enough to permit a substantive review. According to SteadyMed, the FDA requested additional information on certain device specifications and performance testing as well as additional design verification and validation testing on the final Trevyent product.

Following this news, SteadyMed’s share price plummeted by more than 44% in intraday trading, to ultimately close down more than 35% at $3.80 on August 31, 2017.

If you purchased or acquired shares of SteadyMed and would like to speak privately with a securities attorney to learn more about the investigation and your legal rights, visit our website or contact the securities team directly at (800) 254-9493.

Girard Gibbs LLP is one of the nation’s leading firms representing individual and institutional investors in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and has earned Tier-1 rankings and been named in the U.S. Lawyers – Best Law Firms list for five consecutive years.

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
31/08/2017

Underlying

STDYSTEADYMED LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STEADYMED LTD

 PRESS RELEASE
Free
STDY STEADYMED LTD

SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Fi...

SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results SAN RAMON, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2018. Summary Corporate Update: On July 31, 2018, SteadyMed announced that its shareholders voted to approve the previously announced acquisition of...

August 14, 2018 1 EN
 PRESS RELEASE
Free
STDY STEADYMED LTD

SteadyMed Shareholders Approve Proposed Acquisition by United Therapeu...

SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics SAN RAMON, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that SteadyMed shareholders voted to approve the previously announced acquisition of the company by United Therapeutics Corporation (NASDAQ: UTHR) at an extraordinary general meeting of shareholders held on July 30, 2018. SteadyMed shareholders also app...

July 31, 2018 1 EN
 PRESS RELEASE
Free
STDY STEADYMED LTD

HSR Act Waiting Period Terminated for United Therapeutics’ Acquisiti...

HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd. SILVER SPRING, Md. and SAN RAMON, Calif., July 20, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (NASDAQ:UTHR) and SteadyMed Ltd. (NASDAQ:STDY) announced today the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) relating to United Therapeutics’ previously announced acquisition of SteadyMed. As previously announced on April 30, 2018, United Therapeutics and SteadyMed entered into a definitive merger agreement under which Unite...

July 20, 2018 1 EN
STDY STEADYMED LTD

2 directors sold

Two Directors at Steadymed Ltd sold 56,567 shares at 4.500USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

07/04/18 July 4, 2018 1 EN
 PRESS RELEASE
Free
STDY STEADYMED LTD

The Law Offices of Vincent Wong Notifies Investors of an Investigation...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong are investigating the Board of Directors of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to United Therapeutics Corporation. Under the terms of the deal, SteadyMed stockholders will receive $4.46 per share in cash, with an additional $2.63 per share in cash upon achievement of a certain milestone related to SteadyMed’s Trevyent drug-device com...

May 7, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch